Fundraising FoxFreemind Investments
Venture capitalBoston · Seed · 6 people tracked
Find your way into Freemind Investments
Sign up to see every warm intro you have to Freemind Investments
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Freemind Investments team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
FMI is a life science investment platform that pairs an exclusive proprietary database of over 500 companies with a data-driven, de-risking investment formula. It evaluates opportunities at the intersection of a FreeMind organizational score, a federal scientific score, and business potential assessed through detailed due diligence by thousands of key opinion leaders. The fund reviews companies across all stages of development, with emphasis on pre-clinical and clinical-stage programs addressing human health conditions through therapeutics and medical devices. Beyond direct equity investment, FMI offers investees pharma deal-making opportunities including access to Asian markets, co-development, and partnerships. Deal flow is global with a strong emphasis on the US market.
Source: firm website, verified Oct 2, 2026.
Team · 6 people
from the firm's website
What they invest in
from 8 of 8 portfolio companiesBiotech ×7Healthtech ×5AI & Machine Learning ×3Deep Tech ×3Medical Devices ×2Digital Health ×1Longevity ×1
HQs:United States×7
Who they back
founder profiles across 5 portfolio companiesAccelerator rootsportfolio companies that came through a program
Investments · 8 tracked
founders shown can be your intro path
Abalone Bio develops target-activating antibodies for difficult-to-drug disease targets by combining engineered biology with machine learning.
AI & Machine LearningBiotechDeep TechHealthtechSan Francisco, US
Richard Yu(Founder)inGustavo Pesce(Founder)in
Co-investorsGaingelsGravityHarmonix FundHorizons VenturesJude GomilaMetaplanet+4 more
__Twitter.png)
BioKier develops oral products for managing lipids and glucose in type 2 diabetes and cardiometabolic disorders, designed to replicate the metabolic benefits of bariatric surgery through colon-targeted nutrient delivery.
BiotechHealthtechMedical DevicesChapel Hill, US
Jerzy R Szewczyk(Executive Officer, Director)Roger D Nolan(Executive Officer, Director)in
BoardJames Farrelly(Director)
Co-investorsBroadview Ventures
BiotechRockville, US
Jerry Parrott(Executive Officer, Director)in
BoardGlenn Miller(Director)Scott Allocco(Director)Katarzyna Kusmierz(Director)Douglas Clark(Director)Jack Davis(Director)
Co-investorsAbell Foundation, Inc.
General Proximity develops proximity-based technologies for drug discovery and development.
AI & Machine LearningBiotechDeep TechHealthtechSan Francisco, US
Armand Cognetta(Founder)inMatthias PauthnerCorentine Laurin(Principal Scientist, Medicinal Chemistry)Veronica Fulton(Chief of Staff)Benji Dote(EA)Reen Ramos(EA)
Co-investorsY Combinatorage1Felicis VenturesLifespan Vision VenturesLong GameMana Ventures+4 more
Renalis develops prescription digital therapeutics (PDTs), software applications that deliver evidence-based therapeutic interventions to patients under a clinician's care to prevent or treat medical disorders.
Digital HealthHealthtechMedical DevicesChicago, US
Missy Lavender(Executive Officer)in
Co-investorsJumpstart Ventures
BiotechBranford, US
John Richard Nobile(Executive Officer, Director, Promoter)John Davidson(Executive Officer, Director, Promoter)
Co-investorsConnecticut InnovationsLeading Edge Ventures
Thetis is a clinical-stage pharmaceutical company developing TP-317, an oral Resolvin E1 drug that activates the BLT1 receptor to restore tissue and immune balance.
BiotechHealthtechSouthport, US
Frank C Sciavolino(Manager)inGary Mathias(Co-Founder & CEO)inJohn Parkinson(Chief Science Officer)Joyce Steinberg(Chief Medical Officer)Walter Ogier(Manager)Fabio Cataldi(Manager)
Co-investorsConnecticut Innovations
Vincere Biosciences develops small-molecule therapeutics targeting mitochondrial quality control and mitophagy, primarily for neurodegenerative diseases including Parkinson's disease.
AI & Machine LearningBiotechDeep TechLongevity
Co-investorsAlumni VenturesBeiersdorf Innovation FundBeresford VenturesDraper AssociatesLong GamePortal Innovations+1 more
Frequently asked questions
- How many investments has Freemind Investments made?
- Freemind Investments has 8 tracked investments, including 1 dated in the last 24 months.
- What stage does Freemind Investments invest at?
- Freemind Investments invests at the Seed stage.
- What sectors does Freemind Investments focus on?
- Freemind Investments focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Freemind Investments located?
- Freemind Investments is headquartered in Boston, US.
- Who does Freemind Investments co-invest with?
- Freemind Investments most often shares deals with Long Game, Y Combinator, Connecticut Innovations, among 23 tracked co-investors.
Similar investors
Averin Capital is an investment firm focused on the intersection of technology and health, backing teams building companies in areas such as early disease detection, treatment delivery, personalized care, and medical breakthroughs.
BOLD Capital Partners is a venture capital firm backing entrepreneurs and companies working on emerging science and technologies aimed at disrupting large markets and solving major human challenges.
Snatched Ventures is a San Francisco-based early-stage venture capital firm backing DeepTech startups focused on sustainable innovation and operational transformation. It is led by a two-GP team combining corporate development and institutional investment management experience.
Civilization Ventures is a life sciences investor that backs founders in genomics and diagnostics, digital health, and synthetic biology, including gene and cell therapies.
NJF Capital is the venture investment arm of NJF Holdings, the private investment group founded by Nicole Junkermann. It backs transformative entrepreneurs building industry-defining technologies with global scale potential.